<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <STUDY alias="20161115_Tonoyan1" center_name="UNIVERSITY OF BIRMINGHAM" accession="ERP109464">
    <IDENTIFIERS>
      <PRIMARY_ID>ERP109464</PRIMARY_ID>
      <EXTERNAL_ID namespace="BioProject">PRJEB27390</EXTERNAL_ID>
      <SUBMITTER_ID namespace="UNIVERSITY OF BIRMINGHAM">20161115_Tonoyan1</SUBMITTER_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole-genome sequencing to elucidate possible mechanism of E. coli adaptation to antimicrobial therapy</STUDY_TITLE>
      <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
      <STUDY_ABSTRACT>Chemostat continuous culture systems were used to investigate adaptation of E. coli to a novel antimicrobial agent (ITC) and resistance to levofloxacin (LVX) under nutrient limiting environment. Three separate enrichment continuous cultures of E. coli ATCC 25922 were operated (D=0.4 h-1, 480 h) to select for ITC-adapted and LVX-resistant mutants, and compared with selection-free cultures. The derivative culture from the chemostat run under LVX-selection pressure showed resistance towards LVX (MIC of LVX increased 64-fold), and yet, no tolerance was observed towards ITC. Chemostats operated with ITC-selection pressure yielded population with no altered susceptibility towards ITC, as well as LVX. These results revealed that ITC usage is not promoting tolerance to itself, and no cross-resistance to antibiotics.  The aim of this study is to use whole-genome sequence analysis to screen for mutagenesis, to reveal the repertoire of point mutations and to uncover the genetic basis of evolutionary adaptations.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>ENA-FIRST-PUBLIC</TAG>
        <VALUE>2018-06-21</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>ENA-LAST-UPDATE</TAG>
        <VALUE>2018-06-20</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
</STUDY_SET>
